In the United States healthcare system, rapamycin serves multiple critical functions. It's FDA-approved for preventing organ rejection in kidney transplant patients, managing lymphangioleiomyomatosis (LAM), and as an adjunct therapy in certain cardiovascular procedures. Beyond these approved uses, ongoing clinical trials are exploring its potential in age-related diseases, neurodegenerative conditions, and metabolic disorders.